Not all have panned out as planned  however. Under deal terms Tentarix has several opportunities to secure further payment from Gilead should the larger biotech opt to acquire one of the programspecific subsidiaries. The companys structure shares some similarities with those used successfully by Teneobio  IFM Therapeutics and Nimbus Therapeutics 